Immuneering Q3 net loss $12.8M; IMM-1-104 IND cleared, trial recruiting; cash runway into Q3 2024

Immuneering Corp

2022-Q3 EPS reported -$1.41 revenue$316,497

Net loss $12.8M ($0.49/share) vs $8.5M ($0.47) YoY; R&D $9.4M, G&A $3.8M.
Cash and marketable securities $117.2M as of Sept 30, 2022, down from $150.2M at Dec 31, 2021.
IND for IMM-1-104 cleared Sept 2022; Phase 1/2a trial recruiting, first patient expected Q4 2022.
Preclinical data on IMM-6-415 presented at SITC; IND submission expected Q4 2023.
FY 2022 GAAP operating expense guidance reduced to $53-56M from $55-60M; cash runway into Q3 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Immuneering Corp reported the third quarter ended September 30, 2022 results: net income $12.8 million, or $0.49 per share, EPS $0.49 per share. Guidance reaffirmed.

Period: the third quarter ended September 30, 2022
Net income: $12.8 million, or $0.49 per share
EPS: $0.49 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company that aims to create medicines for all patients with solid tumors driven by RAS mutations and other MAPK pathway activation events, today reported financial results for the third quarter ended September 30, 2022, and provided recent business highlights.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

Immuneering Corp filing history →

Source: SEC EDGAR

accession 0001558370-22-017302

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.